KMT2D and lymphoma: Notably, one study found that the treatment of T-lymphoma cells with the histone deacetylase inhibitor chidamide and the hypomethylating agent decitabine induced apoptosis and stopped tumour growth by increasing the interaction between KMT2D and SPI1 (PU.1) [99], which was in the associated region on chromosome 18 in the present study.